Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.

Employees

122

Sector

Biotechnology & Medical Research

More about the company

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 17:30:02 16/09/2026 +04			5-day change	1st Jan Change
0.2415 ^USD	+0.62%		-.--%	+11.81%

09-21	Kintor Pharmaceutical Limited Announces CFO Changes, Effective September 21, 2026	CI
09-21	Kintor Pharmaceutical Limited Announces Resignation of Ming Ming Cheung as Joint Company Secretary with Effect from September 21, 2026	CI

Market Cap	757M 113M 100M 93.67M 85.38M 161M 10.86B 163M 1.13B 439M 5.55B 424M 415M 17.82B	P/E 2024	-2.53x	P/E 2025	-3.96x
Enterprise Value	811M 121M 107M 100M 91.45M 172M 11.63B 174M 1.21B 471M 5.95B 454M 444M 19.08B	EV / Sales 2024	75,794,130x	EV / Sales 2025	28,245,180x
Free-Float	88.01%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Hong Kong S.E.	9939	Delayed
OTC Markets	KNTP.F	Delayed

09-21	Kintor Pharmaceutical Limited Announces CFO Changes, Effective September 21, 2026	CI
09-21	Kintor Pharmaceutical Limited Announces Resignation of Ming Ming Cheung as Joint Company Secretary with Effect from September 21, 2026	CI
09-07	Kintor Pharma Shares Rise as Skin Tone Treatment Inches Closer to Approval After Trial Results	MT
09-07	Kintor Pharmaceutical Limited Announces Successful Completion Of Long-Term Human Safety Trial Of KT-939	CI
08-19	Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-11	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT
06-10	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material	CI
05-28	Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares	RE
05-27	Kintor Pharmaceutical Auditor to Retire; Shares Drop 7%	MT
05-26	Kintor Pharmaceutical Limited Announces Change of Address of Principal Place of Business in Hong Kong, with Effect from 1 June 2026	CI
04-21	Kintor Pharmaceutical's 2026 Sales Jump Past 2025 Full-Year Level	MT
04-20	Kintor Pharmaceutical says ytd 2026 sales revenue at RMB34 million	RE
04-20	Kintor Pharmaceutical Limited Provides Sales Guidance for the Year 2026	CI

Kintor Pharmaceutical Limited Stock OTC Markets

Stocks

KNTP.F

KYG5273B1077

Biotechnology & Medical Research

Valuation: Kintor Pharmaceutical Limited

Chart: Kintor Pharmaceutical Limited

Latest news: Kintor Pharmaceutical Limited

Press Releases: Kintor Pharmaceutical Limited

Quotes and Performance

Price Extremes

Managers and Directors: Kintor Pharmaceutical Limited

Bio Therapeutic Drugs

Financials

Company Profile

Annual profits - Rate of surprise

28/10/23	Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	PU
11/10/23	Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	PU
28/08/23	Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	PU
22/08/23	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
20/07/23	Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	AQ

1 day	+0.63%
1 month	+9.77%
3 months	-1.95%
6 months	-44.19%
Current year	+11.81%

1 month	0.24	0.24
Current year	0.17	0.57
1 year	0.17	0.57
3 years	0.08	0.57
5 years	0.08	11.8
10 years	0.08	11.8

Manager	Title	Age	Since
You Zhi Tong CEO	Chief Executive Officer	64	24/03/2009
Joseph H. J. Cheng DFI	Director of Finance/CFO	48	21/09/2026
Hong Long Lu CTO	Chief Tech/Sci/R&D Officer	49	01/09/2020

Director	Title	Age	Since
Yeung Wai Yim BRD	Director/Board Member	62	12/08/2019
Min Xu BRD	Director/Board Member	61	12/08/2019
You Zhi Tong CHM	Chairman	64	24/03/2009

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KINTOR PHARMACEUTICAL LIMITED	+0.62%	-.--%	-	-	113M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.14%	-0.59%	+52.63%	+128.54%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%

	2024	2025
Net sales	5 0.75 0.66 0.62 0.56 1.06 71.69 1.07 7.48 2.9 36.65 2.8 2.74 117.62	32.68 4.87 4.33 4.04 3.68 6.95 468.59 7.01 48.92 18.96 239.55 18.3 17.9 768.8
Net income	-155M -23.16M -20.58M -19.21M -17.51M -33.02M -2.23B -33.32M -232M -90.07M -1.14B -86.96M -85.07M -3.65B	-200M -29.85M -26.52M -24.75M -22.56M -42.55M -2.87B -42.94M -300M -116M -1.47B -112M -110M -4.71B
Net Debt	-15.68M -2.34M -2.08M -1.94M -1.77M -3.33M -225M -3.36M -23.47M -9.09M -115M -8.78M -8.59M -369M	53.86M 8.03M 7.14M 6.66M 6.07M 11.45M 772M 11.56M 80.62M 31.24M 395M 30.16M 29.51M 1.27B